BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38049334)

  • 21. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 22. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
    Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
    Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
    Hunter BD; Chen YB; Jacobson CA
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose.
    Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days].
    Li YN; Du MY; Li CG; Zhang YQ; Luo WJ; Kou HM; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):739-746. PubMed ID: 34753228
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
    Jain T; Sauter CS; Shah GL; Maloy MA; Chan J; Scordo M; Avecilla ST; Batlevi Y; Dahi PB; Batlevi CW; Lia Palomba M; Giralt SA; Perales MA
    Leukemia; 2019 Oct; 33(10):2540-2544. PubMed ID: 31114023
    [No Abstract]   [Full Text] [Related]  

  • 28. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
    Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study.
    Wang S; Liu A; Wang N; Wang Y; Zhang A; Wang L; Yu W; Li C; Zhang Y; Hu Q
    Front Pediatr; 2022; 10():1100404. PubMed ID: 36727001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
    Meir J; Abid MA; Abid MB
    Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
    Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies.
    Zhu F; Wei G; Zhang M; Zhao H; Wu W; Yang L; Hu Y; Huang H
    Cell Transplant; 2020; 29():963689720919434. PubMed ID: 32314613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma.
    Ganatra S; Redd R; Hayek SS; Parikh R; Azam T; Yanik GA; Spendley L; Nikiforow S; Jacobson C; Nohria A
    Circulation; 2020 Oct; 142(17):1687-1690. PubMed ID: 33104402
    [No Abstract]   [Full Text] [Related]  

  • 35. Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.
    Wang CM; Wu ZQ; Wang Y; Guo YL; Dai HR; Wang XH; Li X; Zhang YJ; Zhang WY; Chen MX; Zhang Y; Feng KC; Liu Y; Li SX; Yang QM; Han WD
    Clin Cancer Res; 2017 Mar; 23(5):1156-1166. PubMed ID: 27582488
    [No Abstract]   [Full Text] [Related]  

  • 36. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
    Khawaja F; Papanicolaou G; Dadwal S; Pergam SA; Wingard JR; Boghdadly ZE; Abidi MZ; Waghmare A; Shahid Z; Michaels L; Hill JA; Kamboj M; Boeckh M; Auletta JJ; Chemaly RF
    Transplant Cell Ther; 2023 Jan; 29(1):10-18. PubMed ID: 36273782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.
    Xu H; Lv Q; Huang L; Cao W; Wang J; Meng F; Li C; Zheng M; Chen L; Mu K; Cheng J; Zhu L; Zhou J; Zhang Y; Wang N; Cao Y
    Cytotherapy; 2023 Feb; 25(2):185-191. PubMed ID: 36283943
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
    Sigmund AM; Denlinger N; Huang Y; Bond D; Voorhees T; Bajwa A; Elder P; Brammer JE; Saad A; Penza S; Vasu S; de Lima M; Jaglowski S; Kittai AS
    Transplant Cell Ther; 2022 Jun; 28(6):342.e1-342.e5. PubMed ID: 35248778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.